Abstract
The major pathologic beta(1)-adrenergic receptor (beta(1)-AR) subtype in heart failure is beta(1)-AR. The authors' laboratory has thus pursued genetic variation of the beta(1)-AR gene at the molecular, cellular, physiologic, and clinical levels as the potential basis for interindividual variability in the response to beta-blocker treatment during heart failure. This article reviews these findings, with emphasis on mechanism of action and future directions.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Adenylyl Cyclases
-
Adrenergic beta-Antagonists / therapeutic use
-
Antihypertensive Agents / therapeutic use
-
Heart Failure / drug therapy*
-
Heart Failure / genetics
-
Heart Failure / physiopathology
-
Humans
-
Myocardium
-
Phenotype
-
Polymorphism, Genetic*
-
Polymorphism, Single Nucleotide
-
Receptors, Adrenergic, beta-1 / genetics*
-
Signal Transduction
Substances
-
Adrenergic beta-Antagonists
-
Antihypertensive Agents
-
Receptors, Adrenergic, beta-1
-
Adenylyl Cyclases